glp-1 ibd Pharmacological interventions for obesity in patients with inflammatory bowel disease: A systematic review of receptor agonist efficacy and safety Recommendations for the safe and

Diabetes Care 43, 446452

GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists are generally well-tolerated, but like all medications, they can cause side effects

Fenfluramine, one of the earliest weight loss drugs, was found over time to be associated with valvular heart disease [48] and was withdrawn from the market by the FDA

Patients should also be monitored for eating disorders if necessary to ensure they are maintaining a healthy relationship with food, and referred to a behavioral health professional where appropriate [101,120]

In the early stages of HF, compensatory mechanisms reduce the impact of the cardiac dysfunction

The accountability of showing up because someone expects you to be there